Dr. Sahai is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
University of Michigan
1500 E Medical Center Dr., C412 MIB
Ann Arbor, MI 48109Phone+1 734-647-8902Fax+1 734-936-4940
Summary
- Dr. Vaibhav Sahai is an oncologist in Ann Arbor, MI and is affiliated with Michigan Medicine. He received his medical degree from Government Medical College Amritsar and has been in practice 13 years. He specializes in gastrointestinal cancer and hematologic oncology and is experienced in gastrointestinal oncology.
Education & Training
McGaw Medical Center of Northwestern UniversityFellowship, Hematology and Medical Oncology, 2010 - 2013
UPMC Medical Education/MercyResidency, Internal Medicine, 2007 - 2010
Harvard UniversityMS, Clinical Epidemiology, 2005 - 2006
Government Medical College AmritsarClass of 2004
Certifications & Licensure
MI State Medical License 2013 - 2026
IL State Medical License 2010 - 2014
PA State Medical License 2007 - 2010- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014
Clinical Trials
- Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Cholangiocarcinoma Start of enrollment: 2014 Dec 09
- Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract Cancer Start of enrollment: 2017 Sep 08
- Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy Start of enrollment: 2019 Mar 28
- Join now to see all
Publications & Presentations
PubMed
- 4 citationsSurvival Analysis of 1140 Patients with Biliary Cancer and Benefit from Concurrent Renin-Angiotensin Antagonists, Statins, or Aspirin with Systemic Therapy.Valerie Gunchick, Rachel L McDevitt, Elizabeth Choi, Katherine Winslow, Mark M Zalupski
The Oncologist. 2023-06-02 - 216 citationsMultimodal mapping of the tumor and peripheral blood immune landscape in human pancreatic cancerNina Steele, Eileen S. Carpenter, Samantha Kemp, Veerin Sirihorachai, Lawrence Delrosario
Nature Cancer. 2020-10-26 - 9 citationsA Phase I/II Open-Label Multicenter Single-Arm Study of FABLOx (Metronomic 5-Fluorouracil Plus nab-Paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin) in Patients wi...Vaibhav Sahai, M. Wasif Saif, Aparna Kalyan, Philip A. Philip, Caio M. Rocha-Lima
Journal of Pancreatic Cancer. 2019-09-25
Journal Articles
- Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid TumorsErin F Cobain, Francis Worden, Scott M Schuetze, Mark M Zalupski, Vaibhav Sahai, Ajjai Alva, Anne F Schott, Moshe Talpaz, JAMA Oncology
Lectures
- Phase III, international, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P + G) versus gemcitabine (G) for resected pancreatic cancer (APACT): Recur...ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020
- A multi-center phase Ib/II study of nal-irinotecan, 5-fluouracil and leucovorin in combination with nivolumab as second-line therapy for patients with advanced unresec...2019 ASCO Annual Meeting - 6/1/2019
- A multicenter phase II trial of rucaparib in combination with nivolumab as maintenance therapy for patients with advanced biliary tract cancer.2019 ASCO Annual Meeting - 6/1/2019
Press Mentions
Rafael Pharmaceuticals to Present Pancreatic & Biliary Tract Cancer Data on CPI-613® (Devimistat) from Its Multicenter, Randomized Phase 1b/2 Trials at the 2021 European Society of Medical Oncology World Gastrointestinal (GI) CongressJune 30th, 2021- FDA Grants Rafael Pharmaceuticals Orphan Drug Designation for CPI-613® (Devimistat) for Treatment of Biliary CancerJune 29th, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
